Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia.

Literature DB >> 25307179

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia.

Lisa Pieri¹, Paola Guglielmelli, Alessandro M Vannucchi.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2015 PMID： 25307179 DOI： 10.1002/ajh.23871

Source DB: PubMed Journal: Am J Hematol ISSN： 0361-8609 Impact factor: 10.047

Keyword Cloud
Cited

× No keyword cloud information.

20 in total

Review 1. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Authors: Daniella M Schwartz; Yuka Kanno; Alejandro Villarino; Michael Ward; Massimo Gadina; John J O'Shea
Journal: Nat Rev Drug Discov Date: 2017-11-06 Impact factor: 84.694

2. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Authors: Daniella M Schwartz; Yuka Kanno; Alejandro Villarino; Michael Ward; Massimo Gadina; John J O'Shea
Journal: Nat Rev Drug Discov Date: 2017-12-28 Impact factor: 84.694

Review 3. JAK inhibitors in dermatology: The promise of a new drug class.

Authors: William Damsky; Brett A King
Journal: J Am Acad Dermatol Date: 2017-01-28 Impact factor: 11.527

Review 4. JAK Inhibitors for Treatment of Alopecia Areata.

Authors: Eddy H C Wang; Brigitte N Sallee; Christina I Tejeda; Angela M Christiano
Journal: J Invest Dermatol Date: 2018-07-26 Impact factor: 8.551

Review 5. Alopecia areata.

Authors: C Herbert Pratt; Lloyd E King; Andrew G Messenger; Angela M Christiano; John P Sundberg
Journal: Nat Rev Dis Primers Date: 2017-03-16 Impact factor: 52.329

Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia.

Review 1. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

2. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.

Review 3. JAK inhibitors in dermatology: The promise of a new drug class.

Review 4. JAK Inhibitors for Treatment of Alopecia Areata.

Review 5. Alopecia areata.

6. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.

Review 7. Understanding autoimmunity of vitiligo and alopecia areata.

Review 8. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.

9. The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms.

10. Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata.